Site icon OncologyTube

Advanced ALK+, RET+ and MET+ NSCLC – 2022 Program: Targeted Therapies Forum – English

For this year’s Targeted Therapies Forum, Dr. Fred R Hirsch, Executive Director, Center for Thoracic Oncology at Mount Sinai; Joe Lowe and Lewis Price Professor of Medicine, Icahn School of Medicine and Associate Director, Biomarker Discovery for TCI, presents Genetic Testing in Lung Cancer.

In this video, Dr. Fred Hirsch discusses the ALK, RET, and MET mutations.

For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Advertisement
Exit mobile version